immune response – Page 49 – Communicable Diseases Research

COVID-19 Adaptive Humoral Immunity Models: Weakly Neutralizing Versus Antibody-Disease Enhancement Scenarios

COVID-19 적응 체액 면역 모델: 약한 중화 대 항체 질병 강화 시나리오

Article

Published on 2022-08-132022-09-12
Journal: Acta biotheoretica [Category] SARS, 진단,

Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults

뉴질랜드 성인에서 BNT162b2 COVID-19 백신의 면역원성

Article

Published on 2022-08-122022-09-11
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] age All participant All participants analysed anti-S IgG Antibody Response baseline Beta BMI BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine Cellular immune response cellular immune responses co-morbidities Cohort COVID-19 COVID-19 disease COVID-19 vaccine declined Delta diabete diabetes diabetics disease dose enrichment Ethnic groups female Gender General population IgG immune response immune responses immunoassay immunogenicity in vitro International Lower Māori median age Microparticle morbidities morbidity naïve neutralise neutralising antibody neutralising response neutralising responses neutralizing capacity New obesity of BNT162b2 Older Older adults omicron other variant other variants Pacific Islander Population prospective cohort study pulmonary disease Quantitative recipient representation response risk robust SARS-CoV-2 vaccine second dose second vaccination serious COVID-19 seroconverted serum sample serum samples strain the vaccine Vaccine variant Viral viral neutralisation Wuhan
[DOI] 10.1016/j.vaccine.2022.07.009 PMC 바로가기 [Article Type] Article

Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers

SARS-CoV-2 S 펩타이드에 대한 T 세포 반응을 평가하기 위한 상용화된 키트. 의료 종사자를 대상으로 한 파일럿 연구

Article

Published on 2022-08-122022-09-11
Journal: Medicina clínica [Category] SARS, 진단, 치료기술,

[키워드] antibody Antibody test antibody tests Automation BNT162b2-mRNA-COVID-19-vaccine Cell mediated immunity CLIA complement Concordance correlation COVID-19 detect dose ELISA English Ensayos de liberación Interferon-gamma feasibility first vaccination group groups HCW Health care worker IFNγ immune response Immunosuppressed individual Infection Inmunidad Mediada por Células interferon Interferon-gamma-release-assays mRNA natural infection number of sample number of samples peptides pilot study positive Quantitative ranged risk S-protein SARS-CoV-2 SARS-CoV-2 N SARS-CoV-2 S SARS-CoV-2 vaccines Sensitivity and specificity Spanish susceptible T-cell Response T-cell responses vaccine dose Vacuna BNT162b2-mRNA-COVID-19.
[DOI] 10.1016/j.medcli.2021.09.013 PMC 바로가기 [Article Type] Article

Chromatin-Associated Molecular Patterns (CAMPs) in sepsis

Reviews

Published on 2022-08-122022-10-05
Journal: Cell Death & Disease [Category] 바이오마커,

Humoral and cellular response in convalescent COVID-19 lupus patients

회복기 COVID-19 루푸스 환자의 체액 및 세포 반응

Article

Published on 2022-08-122022-09-11
Journal: Scientific Reports [Category] SARS, 진단, 치료기술, 치료법, 치료제,

[키워드] accumulated adaptive Analysis analyzed antibodies antibody Antibody Response Antibody titer Antibody titers CD8 cellular response changes in collected confirmed cases confirmed COVID-19 case convalescent convalescent COVID-19 patient convalescent COVID-19 patients convalescent patient Convalescent patients COVID-19 COVID-19 disease COVID-19 incidence COVID-19 infection COVID-19 susceptibility declined decrease died dose dysregulation evaluated flow cytometry Gene expression analysis General population Health care higher risk Hospital admission humoral Humoral and cellular responses hypocomplementemia IgG antibodies immune dysregulation immune response immunological immunological profile Immunological studies Immunosuppression immunosuppressive immunosuppressive therapy impair incidence increase in Infection intensive care lack longitudinal longitudinal changes Lupus medical record memory cell Mild Patient patients PBMC PBMCs PCR-confirmed COVID-19 Prednisone predominant prospective cohort reduction required risk factor Risk factors SARS-CoV-2 IgG SARS-CoV-2 IgG antibodies SARS-CoV-2 IgG antibody severe COVID-19 disease severe disease severity Signaling SLE Surveillance susceptibility sustained Symptom symptom onset T cell Th17 Th2 response therapy were measured
[DOI] 10.1038/s41598-022-17334-5 PMC 바로가기 [Article Type] Article

Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort

스페인 지중해 백인 코호트를 대상으로 한 파일럿 연구에서 HLA-C 대립형질과 COVID-19 심각성 사이의 연관성

Article

Published on 2022-08-122022-09-11
Journal: PLoS ONE [Category] SARS, 유전자 메커니즘,

[키워드] age allele analyzed antiviral response association Asymptomatic cause Cell cell surface class Clinical characteristics clinical presentation Clinical presentations Cohort Comorbidity contrary COVID-19 COVID-19 severity Critical described determine disease epitope Epitopes expressed Factor fatal disease Gender groups HLA HLA allele HLA alleles HLA class I HLA-A HLA-B HLA-B allele HLA-B alleles HLA-C HLA-C allele HLA-C alleles HLA-C1 Host hyperinflammatory state immune response individual Infection involved KIR gene male management mechanism Mild mild infection no significant difference no significant differences outcomes pandemic peptide peptides pilot study recruited SARS-CoV-2 protein SARS-CoV-2 proteins significant difference significant differences small sample size Spain Spanish T cells β2-microglobulin
[DOI] 10.1371/journal.pone.0272867 PMC 바로가기 [Article Type] Article

Defying convention in the time of COVID-19: Insights into the role of γδ T cells

Article

Published on 2022-08-112022-11-15
Journal: Frontiers in Immunology [Category] SARS, 치료제,

A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce

Research

Published on 2022-08-112022-10-05
Journal: Scientific Reports [Category] SARS, 바이오마커, 치료법,

[키워드] activate Activation acute COVID-19 affected Blood C-reactive protein C5a Cluster collected complement Complement activation complex conditions convalescent plasma treatment correlated COVID-19 COVID-19 patients CRP death Deep venous thrombosis demonstrated DVT effector electronic medical records element elevated event HMGB1 homeostasis IgA IgG IgM IL-6 immune response immune system immunological Immunological response incidence Increased Infection Inflammatory response investigated knowledge marker Mortality Necrosis non-specific pathway Patient patients hospitalized PCR-confirmed diagnosis protective factor RAGE remained SARS-COV-2 infection SARS-CoV-2 spike protein shown tissue Treatment viral burden Viral load was collected were assessed
[DOI] 10.1038/s41598-022-17011-7 [Article Type] Research

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Clinical Trial

Published on 2022-08-102022-10-06
Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 진단,

[키워드] 1:1 Administered administration adverse event adverse events age amplifying analysed Analysis antibody concentration Antigen assigned available data BMI booster booster dose Breastfeeding Coalition Contraception COVID-19 pandemic diagnosis of COVID-19 dose Efficacy enrolled evaluated event Evidence exclusion geometric mean titre GMT group healthy homologous IgG immune response inactive increase in initial intramuscular Local Matrix-M median Medical conditions Novavax NVX-CoV2373 outcome participant per-protocol per-protocol population phase 2 trial phase 3 study Placebo placebo-controlled pregnant primary endpoint proportion Protein randomisation randomised Randomly reaction reactogenicity receive Recombinant spike protein recruited regimens Registered Safety SARS-CoV SARS-CoV-2 SARS-CoV-2 strain SARS-CoV-2 vaccine SARS-CoV-2 variant screened serum IgG single booster dose stratified Support the SARS-CoV-2 the vaccine titres Treatment Trial USA vaccination Vaccine variant were excluded women
[DOI] 10.1016/S1473-3099(22)00420-0 PMC 바로가기 [Article Type] Clinical Trial

Characterization of the SARS-CoV-2 B.1.621 (Mu) variant

SARS-CoV-2 B.1.621(Mu) 변종 특성화

Article

Published on 2022-08-102022-09-11
Journal: Science Translational Medicine [Category] SARS, 변종, 진단,